entertainment -WSS

entertainment

author：hotspot 2025-09-30 17:46:09 - browse：61987

Adobe

The Food and Drug Administration has cleared Otsuka Pharmaceutical’s digital treatment for major depressive disorder, offering a new option for millions of people who struggle with the stubborn mental health condition.

Called Rejoyn, the smartphone-based treatment for major depressive disorder symptoms was developed with digital health company Click Therapeutics, and it is intended for use by prescription alongside antidepressants. The six-week program delivers a novel “cognitive-emotional training” technique, in which people are asked to identify and recall faces showing different emotions. Researchers hypothesize that the technique targets the brain’s dorsolateral prefrontal cortex and the amygdala and may “enhance cognitive control over emotional information processing.” Patients also receive cognitive behavioral therapy.

Rejoyn has been in development since 2018, and Otsuka is the first drug company to receive FDA clearance for a digital treatment for a mental health condition. But that landmark comes amid many questions about whether such digital therapeutics deliver their advertised results — and whether they can gain traction with clinicians, insurers, and patients. Prescription digital therapeutics have yet to see a blockbuster success, and several companies have gone out of business trying to create one.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： The United States is paying nearly triple for new Covid vaccines

explore

WSS

What will Novo Nordisk's VC do with its influx of cash?

The biotech scorecard for Q4: 16 stock

Lawsuit highlights wrinkle for disputes over surprise medical bills

Hospitals struggle to profit from CAR

I learned firsthand about improving diversity in clinical trials

Stanford president's case begs question: Who takes blame?

knowledge

entertainment

knowledge

After affirmative action ruling, medical educators look to 'holistic review'

Winning ticket for $1 billion Powerball jackpot sold in California

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

Drug repurposing or repositioning? The language matters

The stability of $0 premiums in Medicare Advantage

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Indian pharmaceutical industry in denial over drug

ChatGPT in medicine: STAT answers readers' burning questions

6 solutions to address cancer drug shortages and others

Wikipedia

6 solutions to address cancer drug shortages and others

The biotech scorecard for Q4: 16 stock

Texas Department of Public Safety speaks out on migrant abuse allegations

Wildfires rage amid heat wave in Greece, prompting evacuations and call for European support

The Karikó problem: Lessons for funding basic research

The United States is paying nearly triple for new Covid vaccines

explore

entertainment

explore

focus